Abstract Details

Title ICCAN-CNS: Update on Patient Navigation and Essential Needs Program for Patients with CNS Tumors

Topic Neuro-oncology

Presentation(s) P12 - Poster Session 12 (11:45 AM-12:45 PM)

Poster/Presentation
Number 6-002

Objective N/A

Background Historically marginalized groups often face significant barriers when it comes to cancer treatment. These barriers are exacerbated in patients with central nervous system (CNS) tumors. The intersection of the social determinants of health with neuropsychiatric, cognitive, motor, sensory, and language deficits makes it especially challenging to adhere to cancer treatment. To address this, we enrolled patients in the Integrated Cancer Care Access Network (ICCAN), a multi-institutional program through Memorial Sloan Kettering Cancer Center’s Immigrant Health and Cancer Disparities Service (IHCD).

Design/Methods Participants are provided with patient navigation services and resource navigation to assist with barriers to treatment adherence and completion. This pilot program specifically looked at neuro-oncology patients with socioeconomic needs. A total of 39 patients were enrolled in the program. Patients were eligible if they were 18 years or older and receiving active treatment or under active surveillance. Participants were asked a series of questions regarding their essential needs such as food access, housing, and financial needs. The interviews were mainly done via phone with some in-person and took approximately 60 minutes to complete. The interviews consisted of demographics, the Alliance Distress Screening Tool, Health Related Social Needs (HRSN) Assessment, Essential Needs Assessment, Patient Satisfaction with Cancer Care, and ICCAN-CNS specific questions. After initial feedback caregivers were permitted to assist patients in completing the survey questions.

Results Patients were matched with resources based on need and were followed at the 2, 4, and 6-month mark to see if any new needs emerged. The top needs expressed among these participants were income, employment issues, food access, and transportation to appointments.

Conclusions Patient feedback was overwhelmingly positive, and we are now protocoling a randomized controlled clinical trial for patients with glioblastoma using the ICCAN intervention. Outcomes will include treatment adherence, completion, quality of life measures, and patient reported outcomes.

Authors/Disclosures
Joshua A. Budhu, MD (Memorial Sloan Kettering Cancer Center) PRESENTER	Dr. Budhu has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. The institution of Dr. Budhu has received research support from BMSF. The institution of Dr. Budhu has received research support from Commonwealth Fund. The institution of Dr. Budhu has received research support from National Cancer Institute . The institution of Dr. Budhu has received research support from Memorial Sloan Kettering Cancer Center. The institution of Dr. Budhu has received research support from United Hospital Fund. Dr. Budhu has received personal compensation in the range of $500-$4,999 for serving as a Peer Reviewer with Medscape.
Cleopatra Elshiekh	Miss Elshiekh has nothing to disclose.
Ashley Phillips (Memorial Sloan Kettering Cancer Center)	No disclosure on file
Ashley M. Marie Rodriguez	Miss Marie Rodriguez has nothing to disclose.
Bharat Narang (Memorial Sloan Kettering Cancer Center)	No disclosure on file
Francesca Gany	Francesca Gany has nothing to disclose.

��ɫ��

��ɫ��